Numerous studies accounted for the involvement of various noncanonical mechanisms in the over-activation of GLI proteins, which explained the ineffectiveness of SMO and upstream inhibitors in the treatment of certain GLI-overexpressing cancers. This evidence concerns the gene SMO and cancer.